WHO Endorses GLP-1 Weight Loss Drugs: An Officially Confirmed Long-Term Track
On December 1, the World Health Organization (WHO) released its first global guideline on GLP-1 drugs for obesity, officially endorsing GLP-1 medications for long-term obesity management.
Key signals:
1. Clear target: Recommends GLP-1 drugs (specifically semaglutide, tirzepatide, liraglutide) for obese or overweight adults with metabolic risk factors, emphasizing use alongside diet, exercise, and behavioral interventions.
2. Emphasis on "long-term, continuous use": WHO advises treating obesity as a chronic, relapsing disease, with medication as part of long-term treatment.
3. "Cautious support" attitude: Recommendation is conditional due to uncertainties in long-term safety, cost pressures, and healthcare system capacities.
4. Accessibility is the biggest issue: WHO and other institutions estimate that by 2030, less than 10% of eligible obese individuals will have access to GLP-1 drugs due to production limitations, high costs, and limited insurance coverage.
Essentially, this guideline represents WHO doing two things globally:
– Medically: Officially upgrading obesity from a "lifestyle issue" to a "chronic disease manageable with long-term medication."
– Market-wise: Pushing GLP-1 from a "star new drug" towards becoming a "global standard treatment tool."
Market potential: From high-priced niche to high-volume at lower prices
– Goldman Sachs and others project the global anti-obesity drug market could reach $100 billion by 2030, a ten-fold increase.
– Research institutions estimate the GLP-1 obesity drug market could reach $60-65 billion by 2035, with a 20%+ CAGR over ten years.
– The economic burden of obesity and overweight is in the trillions of dollars annually, with drug expenditure currently a small fraction of this cost.
A key point: Novo Nordisk and Eli Lilly are proactively reducing prices to gain insurance coverage and market penetration. The business model is shifting from "high price + small population + ultra-high margins" to "low price + high penetration + long-term volume growth."
Logic upgrade: GLP-1 is not just for weight loss, but a "metabolic management platform"
While the WHO guideline discusses "weight reduction," the capital market is focusing on a longer disease chain:
– GLP-1 drugs have been clinically validated to significantly improve weight, blood sugar, blood pressure, and blood lipids.
– Ongoing studies target high-burden diseases like cardiovascular events, sleep apnea, and chronic kidney disease.
– If these "hard endpoints" prove effective, insurers will have incentives to cover costs, upgrading the payment logic from "aesthetics" to "real cost savings."
To summarize for readers:
"Weight loss drugs" are just the first layer of the story. The deeper narrative is about who can turn GLP-1 into a "comprehensive metabolic management platform," potentially securing long-term insurance coverage and valuation premiums.
Beneficiary Targets: Three Main Lines
Eli Lilly :
– Tirzepatide (Mounjaro/Zepbound) sales are growing rapidly, with quarterly revenue now among global pharmaceutical leaders.
– Pipeline advancing multiple indications (obesity, diabetes, cardiovascular, etc.), plus oral GLP-1 (orforglipron) development.
– Characteristic: Aggressive, aiming to be the "standard answer for metabolic platforms."
Novo Nordisk :
– Semaglutide (Ozempic/Wegovy) maintains a large base and has captured markets in multiple countries globally.
– Advancing oral Wegovy and new indication expansions, with extremely stable cash flow.
– Characteristic: First-mover advantage + global channels, a more "defensive" leader.
These two are essentially the core beta of the sector that "must be discussed separately."
1. Second-Tier and Differentiated Players
– $Amgen (AMGN.US)$ : MariTide follows a long-acting multi-target approach, with impressive Phase II weight loss data, viewed as the most likely candidate to become the "third pole."
– Other biotech companies with differentiated targets (e.g., amylin, GIP/GLP-1 complexes) are becoming key targets for big pharma licensing and acquisitions, with event-driven potential.Examples include $Viking Therapeutics (VKTX.US)$ (GLP-1/GIP dual agonist), $Altimmune (ALT.US)$ (GLP-1/GCGR dual agonist), $Structure Therapeutics (GPCR.US)$ (oral small-molecule GLP-1 receptor agonist), and $iBio Inc (IBIO.US)$ (amylin receptor agonist antibody).
1. Broader Beneficiaries: Industry Chain and Service Providers
– CDMO / Manufacturing: Capacity is tight for peptide APIs, high-end injectables, and aseptic filling. Global capacity expansion is underway, with related high-end capacity owners likely to benefit continuously.
– Insurance and Healthcare Management Companies: Those who can truly reduce obesity-related complication costs through "medication + management" will have stronger product pricing power.
Summary
The WHO guideline essentially gives GLP-1 a "global chronic disease pass": It transforms weight loss drugs from a high-priced niche business into a potential long-term track lasting 10-15 years with a market size exceeding $100 billion. Industry leaders benefit from platform advantages, challengers seek differentiation, and the industry chain and digital health sector face re-pricing under this new logic.
Disclaimer: Moomoo Technologies Inc. is providing this content for information and educational use only.
Read more
Comment
Sign in to post a comment
Moomoo Insights
Moomoo Official Account
Decoding markets. Delivering alpha.
32K
Followers
10
Following
96K
Visitors
Follow
Market Insights
Hot Topics Hot Topics
The Week Kicks Off: Davos Forum, PCE Data, Earnings From NFLX、INTC
A jam-packed week: Trump attends Davos, earnings season accelerates with Netflix, Intel reporting, and all eyes turn to Tuesday's Supreme Co
In One Chart
Dec 1, 2025 13:36
December's Must-See Financial Events: FOMC Meeting, Jobs and Inflation Data, Santa Claus Rally, and More
Moomoo Insights
Dec 24, 2025 22:09
U.S. E-commerce vs. Traditional Retailers: Is a Battle Inevitable? A Comparison of Amazon and Walmart
72339195 : Good
Eu : y not calls right
102692757 : obviously influenced by those pharma, how is WHo able to endorse these drugs and telling consumers its safe???? did WHo inform what are the long term health implications for those who consume???
1016551418 : wow
R L Peters : Losing 80-100 lbs can change your life. I did it recently, albeit I did it the old fashioned way. One meal a day, fruit and nuts for snacks, and lots of water. First 75 lbs gone in 169 days.
I hate the idea of recreational diet drugs as someone that has been exposed to medicine and pharmacy my entire life, however it can be an incredible catalyst for purpose and ambition. “Look good, feel good” has always been true for me.
Regardless, this will quickly become one of the fastest and most successful selling pharmaceutical drugs in history. The money is already there.
Slay2dudes : ok
LeBee 102692757 : GLP meds have already saved tens of thousands of lives with minimal side effects for the great majority of users. The studies have been done and evidence shows the benefits for diabetics and the obese are undeniable.